Top Markets
#1 MowCat MowCat +367.01%
#2 龙虾 (Lobster) 龙虾 (Lobster) +68.62%
#3 SODAX SODAX +47.33%
#4 Cortex Cortex +33.11%
#5 DexNet DexNet +23.19%
#6 OpenEden OpenEden +20.03%
#7 MANTRA MANTRA +18.18%
#8 Akedo Akedo +17.22%
#9 Magma Finance Magma Finance +16.03%
#10 wojak wojak +15.31%
Coin of the day
MowCat MowCat
設定
言語
日本
通貨
USD
テーマ
Biotest AG Biotest AG

Biotest AG

BIO
株式のランク #7311
Biotest AG is a German biopharmaceutical company focused on the global... Biotest AG is a German biopharmaceutical company focused on the global development, manufacturing, and commercialization of biological medications. The firm organizes its activities into the Therapy, Plasma & Services, and Other segments. Its product portfolio addresses critical needs in hematology, clinical immunology, and intensive care medicine. Among its offerings are treatments for hemophilia A (such as Haemoctin and Vihuma) and hemophilia B (like Haemonine), covering both acute care and prevention. Biotest also provides therapies for various viral infections, including cytomegalovirus (Cytotect CP), hepatitis B (Fovepta, Hepatect, Zutectra), and varicella zoster (Varitect). Additionally, its products, such as Intratect and IgG Next Generation, are utilized for primary and secondary immune deficiencies, autoimmune disorders, and certain neurological conditions. The company further supplies solutions to manage circulating blood volume (Albiomin, Biseko), address clotting factor deficiencies (Cofact, Fibrinogen), and combat serious infections like community-acquired pneumonia and COVID-19 (Trimodulin), as well as general bacterial infections (Pentaglobin). Established in 1946 as Biotest Serum-Institut GmbH, the company adopted its current name, Biotest Aktiengesellschaft, in 1986. Headquartered in Dreieich, Germany, Biotest Aktiengesellschaft has been operating as a subsidiary of Grifols, S.A. since January 21, 2022.
株価
$47.45
最終同期: 2026-05-13
時価総額
$1.63B
変化（1日）
2.04%
変化（1年）
3.15%
国
DE
取引 Biotest AG (BIO)

カテゴリー

Healthcare
Biotest AG（BIO）の利益
2026 時点の利益 TTM: 0
Biotest AG の最新の財務報告によると、同社の現在の利益は 0 です。2026 年には 0 の利益を上げ、これは 2026 年の利益 0 と 同等 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
Biotest AG の利益の推移（2026 〜 2026）
各年末の利益
年 利益 変化
提供された日付のデータは十分ではありません。
同業他社の利益
企業 利益 利益の差 国
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH